SBI Holdings Of Japan To License Antibodies To AstraZeneca
This article was originally published in PharmAsia News
Executive Summary
Japan's SBI Holdings plans to sell its antibody-drug rights to U.K.-based AstraZeneca to develop and market. SBI Holdings is a venture capital firm that owns SBI Biotech, and expects to earn about $94.7 million from the drug. AstraZeneca's Medimmune is to conduct the clinical trials on drugs for lupus and other autoimmune disorders. SBI hopes to take advantage of AstraZeneca's global presence to get the drug to market. (Click here for more - a subscription may be required